Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 7:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–335 of 335 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional Results available

Photocil (Topical) for the Treatment of Atopic Dermatitis

NCT01992172
Conditions
Atopic Dermatitis
Interventions
Photocil for Atopic Dermatitis, Placebo - Sunscreen (SPF 2)
Drug · Other
Lead sponsor
Applied Biology, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye, Sjogren's Syndrome, Dry Eye
Interventions
Tangible Boost, Placebo
Device · Other
Lead sponsor
Tangible Science
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Needham, Massachusetts
Conditions
Neuralgia, Postherpetic
Interventions
Lamictal in the treatment of Post-Herpetic Neuralgia
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 85 Years
Timeline
Started 2005
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Phenylketonuria, PKU
Interventions
RDD to Palynziq
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chevy Chase, Maryland
Conditions
Uncontrolled Asthma, Young Adults
Interventions
Medication Therapy Management (MTM) Video Telehealthcare, Electronic Adherence Self-Management (EAM)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years to 35 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
21
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 12 more
Conditions
Asthma
Interventions
Fluticasone furoate/Vilanterol Inhalation Powder, Fluticasone Furoate Inhalation Powder, Placebo Inhaltion Powder
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Bell Gardens, California • Huntington Beach, California • Long Beach, California + 19 more
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
CorEvitas
Network
Eligibility
10 Years to 15 Years
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2099
U.S. locations
1
States / cities
Waltham, Massachusetts
Conditions
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
Interventions
PBA-0111
Drug
Lead sponsor
Pure Biologics S.A.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Shreveport, Louisiana
Conditions
Atopic Dermatitis
Interventions
Tacrolimus Ointment 0.1%, Protopic® ointment, 0.1%, Placebo of Tacrolimus Ointment
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
18 Years and older
Enrollment
1,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
60
States / cities
Tempe, Arizona • Anaheim, California • Bell Gardens, California + 43 more
Conditions
Atopic Dermatitis
Interventions
Tilrekimig, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
14
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 11 more
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals), Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray, Placebo
Drug
Lead sponsor
Sandoz
Industry
Eligibility
12 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
Austin, Texas • Kerrville, Texas • Live Oak, Texas + 3 more
Conditions
Atopic Dermatitis, Eczema, Atopic
Interventions
PF-08049820, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
17
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Huntington Beach, California + 9 more
Conditions
Atopic Dermatitis, Plaque Psoriasis
Interventions
PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%, PF-07038124 ointment 0.06%
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
23
States / cities
Encinitas, California • Los Angeles, California • Cape Coral, Florida + 17 more
Conditions
Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung, Pulmonary Hypertension, Usual Interstitial Pneumonia
Interventions
Not listed
Lead sponsor
Cosmos Rx, Inc
Industry
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Norfolk, Virginia
Conditions
Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
Interventions
Torvutatug samrotecan, Bevacizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
26
States / cities
Anchorage, Alaska • Miami, Florida • Indianapolis, Indiana + 21 more
Conditions
Asthma
Interventions
Omalizumab
Drug
Lead sponsor
DiMango, Emily, M.D.
Individual
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
New York, New York
Completed Phase 1 Interventional Accepts healthy volunteers

DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin

NCT02300363
Conditions
Healthy
Interventions
Treatment A (rosuvastatin), Treatment B (LX4211), Treatment C (rosuvastatin + 400 mg LX4211 administered concomitantly)
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Evansville, Indiana
Conditions
Palmar-Plantar Erythrodysesthesia, Breast Cancer
Interventions
Cream, 0.1% Uracil Cream
Drug
Lead sponsor
Nanometics (d.b.a. PHD Biosciences)
Industry
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Birmingham, Alabama • Palm Springs, California • Evansville, Indiana + 3 more
Conditions
Ebola Virus Disease, Marburg Virus Disease
Interventions
cAd3-Marburg, cAd3-EBO-S
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
Eosinophilic Esophagitis
Interventions
CC-93538, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
12 Years to 75 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
115
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 97 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.

NCT02932891
Conditions
Atopic Dermatitis
Interventions
DSXS topical
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hawthorne, New York
Conditions
Hand Foot Syndrome, Palmar Plantar Erythrodysesthesia
Interventions
sildenafil citrate
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Asthma, Lung Diseases
Interventions
Problem Solving, Attention Control
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 90 Years
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania